BMS’ Cell Therapy For Lymphoma On Track For EU-Wide Approval

Breyanzi’s EU Approval Will Introduce A Third CAR-T Therapy To The LBCL Market

 
• By Vibha Sharma
gene therapy
Each dose of Breyanzi is created by collecting and genetically modifying a patient’s own immune cells to treat their cancer • Source: Alamy (Alamy Stock Photo)

More from Cell & Gene Therapies

More from Advanced Technologies